South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...

Celltrion Inc., a major South Korean biopharmaceutical firm, said Wednesday it will buy back 100 billion won (US$69 million) worth of its own stocks to boost its shareholder value. Celltrion will ...

South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...

Celltrion announces 100 billion won share buyback, starts market purchase tomorrow Celltrion to start market share buyback ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® ...

Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar ...

INCHEON, South Korea, February 19, 2025--(BUSINESS WIRE)--Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt ® (CT-P42, aflibercept), a biosimilar to Eylea ...